Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Rocco Coli"'
Autor:
Theresa L. Johnson, Steven Kazmirski, Simon Low, Cyrille Kuhn, Robert V. Stanton, Yuan-Hua Ding, Gayatri D. Deshmukh, Jessie M. English, Haile Tecle, Glen Rennie, Ping Ye, Hu Liu, Joseph Wu, Alan C. Cheng, Suzanne L. Jacques, Rocco Coli, Frederic Feru
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:4885-4891
By targeting an extended region of the conventional 'DFG-out' pocket of p38alpha, while minimizing interactions with the specificity pocket and eliminating interactions with the adenine binding site, we are able to design and synthesize a number of p
Autor:
Rocco Coli, Joseph W. E. Worrall, Wade Diehl, Jonathan P DiNitto, Gayatri D. Deshmukh, Joseph Wu, Yan Zhang, Jessie M. English, Suzanne L. Jacques
Publikováno v:
Journal of Biochemistry. 147:601-609
The activation of receptor tyrosine kinases (RTKs) is tightly regulated through a variety of mechanisms. Kinetic studies show that activation of c-Kit RTK occurs through an inter-molecular autophosphorylation. Phosphopeptide mapping of c-Kit reveals
Autor:
Rocco Coli, B. Ganesh Bhat, Leyu Wang, Meg McLaughlin, Patricia Soulard, Ming-Shang T. Kuo, Jennifer Moore, Brendan Connolly, Can C. Ozbal, Jessica Stevens, William A. LaMarr
Publikováno v:
Analytica Chimica Acta. 627:105-111
Several recent reports suggest that stearoyl-CoA desaturase 1 (SCD1), the rate-limiting enzyme in monounsaturated fatty acid synthesis, plays an important role in regulating lipid homeostasis and lipid oxidation in metabolically active tissues. As se
Autor:
Darcy Kohls, Simon Low, Glen Rennie, Yuan-Hua Ding, Cyrille Kuhn, Frederic Feru, Michael Kothe, Rocco Coli
Publikováno v:
Chemical Biology & Drug Design. 70:540-546
Polo-like kinase 1 is an important regulator of cell cycle progression whose over-expression is often associated with oncogenesis. Polo-like kinase 1 hence represents an attractive target for cancer intervention. BI 2536 (Boehringer Ingelheim, Ingelh
Autor:
Simon Low, Rocco Coli, Yuan-Hua Ding, Alan C. Cheng, Alissa L. Sheils, Cyrille Kuhn, Thomas A. Wynn, Theresa L. Johnson, Jim Nonomiya, Suzanne L. Jacques, Darcy Kohls, Cristina Lewis, Michael Kothe, Kimberly A. Verdries, Christine Loh
Publikováno v:
Biochemistry. 46:5960-5971
Polo-like kinase 1 (Plk1) is an attractive target for the development of anticancer agents due to its importance in regulating cell-cycle progression. Overexpression of Plk1 has been detected in a variety of cancers, and expression levels often corre
Publikováno v:
Gene. 279:81-89
The autosomal recessive disorder familial dysautonomia (FD) has recently been demonstrated to be caused by mutations in the IKBKAP gene, so named because an initial report suggested that it encoded an IkB kinase complex associated protein (IKAP). Two
Autor:
Berish Y. Rubin, Rocco Coli, Matthew J. Rork, Josef Ekstein, Elizabeth Kichula, Ira W. Daly, Sabrina A. Volpi, Sylvia L. Anderson
Publikováno v:
The American Journal of Human Genetics. 68:753-758
The defective gene DYS, which is responsible for familial dysautonomia (FD) and has been mapped to a 0.5-cM region on chromosome 9q31, has eluded identification. We identified and characterized the RNAs encoded by this region of chromosome 9 in cell
Autor:
Steven Kazmirski, Nidhi Jhawar, Jianxing Shao, Emilia Bora, Haile Tecle, Suzanne Jacques-O’Hagan, Yuan-Hua Ding, Deb Moshinsky, Rocco Coli, Jeffrey F. Ohren, Joe Wu, Michael Kothe, Yanhong Li, Julie Penzotti
Publikováno v:
Bioorganicmedicinal chemistry letters. 19(1)
An approach and preliminary results for utilizing legacy MEK inhibitors as templates for a reiterative structural based design and synthesis of novel, type III NCKIs (non-classical kinase inhibitors) is described. Evidence is provided that the MEK-po
Autor:
Michael, Kothe, Darcy, Kohls, Simon, Low, Rocco, Coli, Glen R, Rennie, Frederic, Feru, Cyrille, Kuhn, Yuan-Hua, Ding
Publikováno v:
Chemical biologydrug design. 70(6)
Polo-like kinase 1 is an important regulator of cell cycle progression whose over-expression is often associated with oncogenesis. Polo-like kinase 1 hence represents an attractive target for cancer intervention. BI 2536 (Boehringer Ingelheim, Ingelh